Dirk Wuttge
1 – 10 of 52
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Treatment with mycophenolate mofetil is associated with improved nailfold vasculature in systemic sclerosis
(
- Contribution to journal › Article
- 2023
-
Mark
Validation of the Swedish version of PROMIS-29v2 and FACIT-Dyspnea Index in patients with systemic sclerosis
(
- Contribution to journal › Article
-
Mark
Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study
(
- Contribution to journal › Article
- 2022
-
Mark
Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension
(
- Contribution to journal › Article
- 2021
-
Mark
A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis : The UPSIDE study protocol
(
- Contribution to journal › Article
-
Mark
An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod
(
- Contribution to journal › Article
-
Mark
Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension : call for a refined assessment
(
- Contribution to journal › Article
- 2020
-
Mark
Pulmonary arterial hypertension in systemic sclerosis - When criteria and pathobiology differ
(
- Contribution to journal › Letter
-
Mark
Mycophenolate mofetil for systemic sclerosis : Drug exposure exhibits considerable inter-individual variation-a prospective, observational study
(
- Contribution to journal › Article
-
Mark
Type III, IV, and VI Collagens Turnover in Systemic Sclerosis – a Longitudinal Study
(
- Contribution to journal › Article